Abiopharma

🔍 Mat Ishbia (Director)

Company: UWM Holdings Corp (UWMC)

Report Date: 2026-08-05

Detailed Transactions and Holdings:

• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-08-05 | Code: H | shares_owned_after: 408,131.00 | Footnotes: F1
• Acquired 15,000,000 shares of Class A Warrants (right to buy) at $6.0 per share (Derivative)
  Date: 2026-08-05 | Code: A | Expires: 2036-08-05 | equity_swap_involved: 0 | shares_owned_after: 15,000,000.00 | transaction_form_type: 4 | Footnotes: F3, F2, F4
• Acquired 15,000,000 shares of Class B Warrants (right to buy) at $2.0 per share (Derivative)
  Date: 2026-08-05 | Code: A | Expires: 2036-08-05 | equity_swap_involved: 0 | shares_owned_after: 15,000,000.00 | transaction_form_type: 4 | Footnotes: F3, F2, F4

Footnotes:

• F1: These shares are held directly by Mat Ishbia and SFS Corp. has no interests in these shares.
• F2: The Class A Warrants and the Class B Warrants are not exercisable until the Issuer obtains stockholder approval of the exercise of such Warrants pursuant to the rules of the New York Stock Exchange
• F3: Pursuant to a Securities Purchase Agreement dated as of August 5, 2026, by and among the Issuer, certain funds or investment vehicles advised, managed by, or otherwise affiliated with Oaktree Capital Management, L.P.,, Mat Ishbia, SFS Holding Corp. and SFS Group Capital, LLC ("SFS Capital"), SFS Capital purchased 150,000 shares of Series A-1 Preferred Stock of the Issuer with an issue price of $1,000 per share, together with Class A Warrants and Class B Warrants, each to purchase 15,000,000 shares of the Company's Class A Common Stock, for an aggregate purchase price of $1,500,000.
• F4: These securities are held directly by SFS Capital, and indirectly by Mat Ishbia. Mat Ishbia is the manager and beneficially owns 75% of the equity interests in SFS Capital. By virtue of its relationship with Mat Ishbia, a director and the CEO of the Issuer, SFS Capital may be deemed to be a director by deputization.